Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DCTH | DELCATH SYSTEMS, INC. | 2026-04-02 15:04:48 | 9.63 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DCTH | 0000872912 | DELCATH SYSTEMS, INC. | US24661P8077 | 549300NVPLITUM6URT02 | 061245881 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 566 QUEENSBURY AVENUE | QUEENSBURY | NY | 12804 | UNITED STATES | US | (518) 743-8892 | 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804 | 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804 | DELCATH SYSTEMS, INC. | — | — | — | — | http://delcath.com | 419,743,586 | 34,691,671 | 34,746,187 | Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine). | 2026-04-02 18:21:47 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 419,743,586 | 214,060,369 | 104.0728 | 34,746,187 | 1,343,049 | 4.0207 |
| 2024 | 205,683,217 | 124,016,064 | 151.8555 | 33,403,138 | 8,840,446 | 35.9914 |
| 2023 | 81,667,153 | -31,866,177,847 | -99.7444 | 24,562,692 | 14,500,704 | 144.1137 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Martha Rook | Chief Operating Officer | 2025 | 460,833 | — | — | 180,000 | 0 | 2,024,228 |
| Vojislav Vukovic | Chief Medical Officer | 2025 | 488,000 | — | — | 184,000 | 0 | 2,055,395 |
| Gerard Michel | Chief Executive Officer | 2025 | 635,707 | — | — | 355,000 | 0 | 5,765,258 |
| Vojislav Vukovic | Chief Medical Officer | 2024 | 465,000 | — | — | 210,600 | 0 | 1,085,612 |
| Gerard Michel | Chief Executive Officer | 2024 | 560,622 | — | — | 366,756 | 0 | 2,157,414 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 156 |
| 2024 | 96 |
| 2023 | 76 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 85,231,000 | 37,205,000 | 2,065,000 |
| Cost Of Revenue | 11,797,000 | 6,188,000 | 635,000 |
| Gross Profit | 73,434,000 | 31,017,000 | 1,430,000 |
| Research And Development Expenses | 29,246,000 | 13,874,000 | 17,502,000 |
| General And Administrative Expenses | 43,528,000 | 29,553,000 | 22,110,000 |
| Operating Expenses | 72,774,000 | 43,427,000 | 39,612,000 |
| Operating Income | 660,000 | -12,410,000 | -38,182,000 |
| Net Income | 2,700,000 | -26,386,000 | -47,678,000 |
| Earnings Per Share Basic | 0.08 | -0.93 | -2.94 |
| Earnings Per Share Diluted | 0.07 | -0.93 | -2.94 |
| Weighted Average Shares Outstanding Basic | 35,821,157 | 28,511,393 | 16,229,931 |
| Weighted Average Shares Outstanding Diluted | 39,919,557 | 28,511,393 | 16,229,931 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 43,454,000 | 32,412,000 | 12,646,000 |
| Marketable Securities Current | 47,582,000 | 20,821,000 | 19,808,000 |
| Accounts Receivable | 11,744,000 | 10,890,000 | 241,000 |
| Inventories | 10,252,000 | 6,933,000 | 3,322,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 119,530,000 | 73,760,000 | 37,158,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,166,000 | 1,790,000 | 1,352,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 4,102,000 | 2,829,000 | 1,455,000 |
| Total Assets | 123,632,000 | 76,589,000 | 38,613,000 |
| Accounts Payable | 2,658,000 | 961,000 | 1,012,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | 0 | 5,239,000 |
| Other Liabilities Current | 8,191,000 | 5,078,000 | 5,249,000 |
| Total Liabilities Current | 10,950,000 | 6,144,000 | 16,448,000 |
| Long Term Debt | — | 0 | 10,150,000 |
| Other Liabilities Non Current | 628,000 | 766,000 | 840,000 |
| Total Liabilities Non Current | 1,463,000 | 1,699,000 | 6,388,000 |
| Total Liabilities | 12,413,000 | 7,843,000 | 22,836,000 |
| Common Stock | 347,000 | 331,000 | 228,000 |
| Retained Earnings | -528,848,000 | -531,548,000 | -505,162,000 |
| Accumulated Other Comprehensive Income | 575,000 | 82,000 | 135,000 |
| Total Shareholders Equity | 111,219,000 | 68,746,000 | 15,777,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 238,000 | 134,000 | 128,000 |
| Share Based Compensation Expense | — | — | — |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 854,000 | 10,649,000 | -125,000 |
| Change In Inventories | 3,319,000 | 3,611,000 | 1,324,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 4,766,000 | 479,000 | -199,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 22,516,000 | -18,681,000 | -31,251,000 |
| Purchases Of Marketable Securities | 93,216,000 | 52,453,000 | 19,651,000 |
| Sales Of Marketable Securities | 68,173,000 | 52,031,000 | 0 |
| Acquisition Of Property Plant And Equipment | 1,547,000 | 559,000 | 58,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -26,590,000 | -981,000 | -19,709,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 481,000 | 250,000 | 123,000 |
| Repurchase Of Common Stock | 6,000,000 | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | 10,600,000 | 6,313,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 15,048,000 | 39,410,000 | 51,778,000 |
| Change In Cash | 11,042,000 | 19,716,000 | 874,000 |
| Cash At End Of Period | 43,454,000 | 32,412,000 | 12,646,000 |
| Income Taxes Paid | 1,545,000 | — | — |
| Interest Paid | 0 | 1,236,000 | 1,459,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0.08 | -0.93 | -2.94 |
| Price To Earnings Ratio | 126.25 | -12.9462 | -1.415 |
| Earnings Growth Rate | -108.6022 | -68.3673 | -28.6408 |
| Price Earnings To Growth Ratio | -1.1625 | 0.1894 | 0.0494 |
| Book Value Per Share | 3.1048 | 2.4112 | 0.9721 |
| Price To Book Ratio | 3.253 | 4.9934 | 4.2794 |
| Ebitda | 4,483,000 | -25,852,000 | -46,050,000 |
| Enterprise Value | — | 310,865,171.72 | 70,259,512.96 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | 0 | 0.9754 |
| Capital Expenditures | 1,614,000 | 572,000 | 58,000 |
| Free Cash Flow | 20,902,000 | -19,253,000 | -31,309,000 |
| Return On Equity | 0.0243 | -0.3838 | -3.022 |
| One Year Beta | 1.4209 | 1.1364 | 0.0044 |
| Three Year Beta | 1.0096 | 0.5945 | 0.6759 |
| Five Year Beta | 0.9171 | 0.5064 | 0.4592 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Pennell Sandra | Chief Financial Officer | 2026-03-06 | 5,533 | A | 77,018 |
| MICHEL GERARD J | Director, CHIEF EXECUTIVE OFFICER | 2026-03-02 | 11,200 | A | 342,034 |
| MICHEL GERARD J | Director, CHIEF EXECUTIVE OFFICER | 2026-02-17 | 195,000 | A | 195,000 |
| MICHEL GERARD J | Director, CHIEF EXECUTIVE OFFICER | 2026-02-17 | 97,500 | A | 97,500 |
| Rook Martha S. | CHIEF OPERATING OFFICER | 2026-02-17 | 56,500 | A | 56,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 5,935,548 | 587,678 | 10.1 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 3,081 | 305 | 10.1016 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 465 | 46 | 10.1087 |
| Invesco Ltd. | 2025-12-31 | 172,660 | 17,095 | 10.1 |
| ADAR1 Capital Management, LLC | 2025-12-31 | 2,266,289 | 224,385 | 10.1 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 13,450 | 133,289.5 | 0.0096 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class P Shares | GMAPX | 53,844 | 533,594.04 | 0.0902 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R6 Shares | GCSUX | 53,844 | 533,594.04 | 0.0902 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Investor Shares | GDSTX | 53,844 | 533,594.04 | 0.0902 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R | GDSRX | 53,844 | 533,594.04 | 0.0902 |